TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6175803

Group type: EXPERIMENTAL
Intervention: Alinidine 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alinidine 40 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alinidine 40 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clonidine 0.1 mg
Number of subjects: 0
Study: 28411006

Group type: EXPERIMENTAL
Intervention: 0.5% minocycline mouth rinse
Number of subjects: 14

Group type: COMPARATOR
Intervention: 0.2% minocycline mouth rinse
Number of subjects: 14
Study: 27261170

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (cycling 3×/week for 30min at moderate to vigorous intensity)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo group (supervised myofascial release training 3×/week, approx. 30min)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 83
Study: 24097260

Group type: COMPARATOR
Intervention: No self-harm at baseline
Number of subjects: 2042

Group type: EXPERIMENTAL
Intervention: Risk factors identified
Number of subjects: 2042

Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 2042
Study: 21898040

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX), 400 mg/tid from 24 h before to 24 h after coronary angioplasty
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control group with routine treatment and no PTX
Number of subjects: 286
Study: 18822413

Group type: EXPERIMENTAL
Intervention: Extended-release (ER) niacin 1000 mg/day
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 17996517

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study: 16255470

Group type: EXPERIMENTAL
Intervention: COX‐2 inhibitors (COX‐2i)
Number of subjects: 127
Study: 12501222

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 287

Group type: COMPARATOR
Intervention: Diclofenac 75 mg twice daily plus omeprazole 20 mg daily
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 287

Group type: COMPARATOR
Intervention: Diclofenac plus omeprazole
Number of subjects: 287
Study: 9614767

Group type: EXPERIMENTAL
Intervention: Nasal challenge test with allergen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nasal challenge test with placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (20 atopic subjects not sensitized to allergens)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 100
Study: 7652027

Group type: EXPERIMENTAL
Intervention: Contralateral 95 dB SPL white-noise stimulation (S2)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Visual attention task (S3)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combined stimulation (S4)
Number of subjects: 7
Study: 2649340

Group type: EXPERIMENTAL
Intervention: Premeal injections of short‐acting insulin and intermediate‐acting insulin at bedtime (using Novopen)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional three times daily injection regimen
Number of subjects: 18
Study: 334207

Group type: EXPERIMENTAL
Intervention: Anidoxime 75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anidoxime 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dihydrocodeine 50 mg
Number of subjects: 0
Study: 31724474

Group type: EXPERIMENTAL
Intervention: Children living in villages
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Overall population of children studied
Number of subjects: 1080
Study: 31250285

Group type: EXPERIMENTAL
Intervention: rTMS treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: SHAM treatment
Number of subjects: 29
Study: 28481614

Group type: EXPERIMENTAL
Intervention: Intensive addiction/housing case management (AHCM)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Housing support group (HSG)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 181
Study: 27136904

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol/gestodene contraceptive patch
Number of subjects: 36
Study: 24206154

Group type: EXPERIMENTAL
Intervention: PTT alone ('plastic' condition)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: SP‐PTT hybrid with an SP who did not engage in any superfluous conversation ('perfunctory' condition)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: SP‐PTT hybrid with an SP who was trained to offer small talk and banter ('pleasant' condition)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Communication skills across all groups
Number of subjects: 145

Group type: COMPARATOR
Intervention: Technical skills scores among groups
Number of subjects: 145
Study: 21241520

Group type: EXPERIMENTAL
Intervention: Mannitol challenge
Number of subjects: 28
Study: 19951541

Group type: EXPERIMENTAL
Intervention: Simplified NPWT (gauze + continuous suction with hospital central negative pressure -10.64 kPa for 24 hs)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional NPWT (sponge + interrupted suction with purpose-designed suction appliance -16.63 kPa for 24 hs)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Simplified NPWT
Number of subjects: 44
Study: 17075662

Group type: EXPERIMENTAL
Intervention: Computer-integrated patient-controlled epidural analgesia (CI-PCEA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous Epidural Infusion (CEI)
Number of subjects: 40
Study: 14564324

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1379
Study: 11324201

Group type: EXPERIMENTAL
Intervention: Dental health education involving teachers
Number of subjects: 430

Group type: COMPARATOR
Intervention: Dental health education for children alone
Number of subjects: 430

Group type: COMPARATOR
Intervention: Dental health education for children with parents
Number of subjects: 430
Study: 8680050

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with cyclosporine and maintenance corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose intravenous corticosteroids (i.v. steroids) and conventional triple therapy
Number of subjects: 0
Study: 1740541

Group type: EXPERIMENTAL
Intervention: Transdermal delivery system (TDS) with 20 mg GTN, applied for 4 successive days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal delivery system (TDS) releasing 15 mg GTN/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transdermal delivery system (TDS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sublingually administered GTN
Number of subjects: 10
Study: 6377291

Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure for 6 months
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both health education and self-monitoring
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 115
Study: 31835036

Group type: EXPERIMENTAL
Intervention: Single-cell genomics
Number of subjects: 12715
Study: 28513525

Group type: EXPERIMENTAL
Intervention: Exercise with soft tissue manipulation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (triple therapy of needle, moxibustion, and cupping jar)
Number of subjects: 0
Study: 27110915

Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) and HIPEC
Number of subjects: 1125

Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 1125
Study: 24823671

Group type: EXPERIMENTAL
Intervention: Aggressive arm (second-look surgery)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional arm (no second-look surgery)
Number of subjects: 216
Study: 22038623

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (BiV) ON
Number of subjects: 11

Group type: COMPARATOR
Intervention: Biventricular pacing (BiV) OFF
Number of subjects: 11
Study: 19464558

Group type: EXPERIMENTAL
Intervention: Live attenuated H7N3 virus vaccine (10^7.5 TCID50 administered by nasal spray, 2 doses, 5 weeks apart)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Live attenuated H7N3 virus vaccine (first dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Live attenuated H7N3 virus vaccine (second dose)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Live attenuated H7N3 virus vaccine
Number of subjects: 21
Study: 17699438

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 0
Study: 14992920

Group type: EXPERIMENTAL
Intervention: TachoComb
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dalteparin 5,000 IU
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TachoComb and Dalteparin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional surgical hemostasis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Enoxaparin 4,000 IU
Number of subjects: 80
Study: 12047396

Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg plus metformin 1000 mg b.i.d.
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg plus metformin 1000 mg b.i.d.
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg plus metformin 1000 mg b.i.d. in patients with HbA1c > 9.5%.
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg in patients with low HbA1c levels (<or= 8%) at baseline.
Number of subjects: 467

Group type: COMPARATOR
Intervention: Metformin 1000 mg b.i.d.
Number of subjects: 467
Study: 11317199

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg o.d.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg o.d.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined therapy (Losartan + Enalapril)
Number of subjects: 9
Study: 9207352

Group type: EXPERIMENTAL
Intervention: 15% undecylenic acid cream
Number of subjects: 573
Study: 11767425

Group type: EXPERIMENTAL
Intervention: Pethidine 0.5%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pethidine 1%
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pethidine 1.5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 40
Study: 3304029

Group type: EXPERIMENTAL
Intervention: Ketanserin (mean dose 167 mg/day)
Number of subjects: 21
Study: 29891011

Group type: EXPERIMENTAL
Intervention: New Start intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 26153783

Group type: EXPERIMENTAL
Intervention: Distributed practice (practice blocks spaced in time)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Massed practice (all practices performed in 1 day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simulator‐integrated tutor function
Number of subjects: 40
Study: 23764867

Group type: COMPARATOR
Intervention: Heated humidifier (HH)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 29
Study: 23205917

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 19577808

Group type: EXPERIMENTAL
Intervention: Bifrontal (BF) ultra-brief ECT at 1.5 times seizure threshold (ST)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Unilateral (UL) ultra-brief ECT at 6 times seizure threshold (ST)
Number of subjects: 64
Study: 18655558

Group type: EXPERIMENTAL
Intervention: Fulu Baoxinping (FLBXP) oral liquid 10 mL thrice a day for 28 days
Number of subjects: 240

Group type: COMPARATOR
Intervention: Wenxin Granule 9 g thrice a day for 28 days
Number of subjects: 240
Study: 15936933

Group type: EXPERIMENTAL
Intervention: BUD/F (2x100/6 microg) administered in the evening (2000 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12651656

Group type: EXPERIMENTAL
Intervention: Ephedrine 70 microg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ephedrine 110 microg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 120
Study: 10655024

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily
Number of subjects: 97
Study: 9007884

Group type: EXPERIMENTAL
Intervention: Epidural morphine (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no epidural morphine)
Number of subjects: 0
Study: 1505054

Group type: EXPERIMENTAL
Intervention: Levoprotiline
Number of subjects: 58

Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 58
Study: 29618079

Group type: EXPERIMENTAL
Intervention: Hand massage (two 20-minute sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hand holding (two 20-minute sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (two 20-minute rest periods)
Number of subjects: 60
Study: 26891115

Group type: EXPERIMENTAL
Intervention: DACC impregnated dressing
Number of subjects: 543

Group type: COMPARATOR
Intervention: Standard surgical dressing (SSD)
Number of subjects: 543
Study: 24957557

Group type: EXPERIMENTAL
Intervention: IMN-RT (Internal Mammary Node Radiotherapy)
Number of subjects: 68

Group type: COMPARATOR
Intervention: IMN-RT simulation (for left-sided patients)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IMN-RT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IMN-RT (for right-sided patients)
Number of subjects: 68
Study: 22730932

Group type: EXPERIMENTAL
Intervention: Tooty Fruity Vegie intervention
Number of subjects: 18
Study: 20837588

Group type: EXPERIMENTAL
Intervention: Dexamethasone (moderately early treatment)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Dexamethasone (delayed treatment)
Number of subjects: 721
Study: 18303192

Group type: EXPERIMENTAL
Intervention: Galantamine treatment
Number of subjects: 138

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 138
Study: 16491309

Group type: EXPERIMENTAL
Intervention: Electrical Impedance Scanning (EIS) with Clinical Breast Examinations (CBE) on 189 women prior to scheduled breast biopsy.
Number of subjects: 1550

Group type: COMPARATOR
Intervention: Electrical Impedance Scanning (EIS) on 1361 asymptomatic women visiting clinics for routine annual well-woman examination.
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: Positive EIS examination in women.
Number of subjects: 1550
Study: 14578147

Group type: EXPERIMENTAL
Intervention: Individualized psychoeducational intervention
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 558
Study: 10872642

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 281
Study: 9344701

Group type: EXPERIMENTAL
Intervention: Anti-GAD positive NIDDM-SF patients
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: NIDDM-SF patients
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Combination of serological marker (anti-GAD) and genetic marker (HLA-DRB1)
Number of subjects: 420
Study: 8410865

Group type: EXPERIMENTAL
Intervention: Active SAS unit
Number of subjects: 23

Group type: COMPARATOR
Intervention: Inactive placebo unit
Number of subjects: 23
Study: 3513347

Group type: EXPERIMENTAL
Intervention: Prophylactic oophorectomy
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (no oophorectomy)
Number of subjects: 280
Study: 29794545

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (video clips of rehabilitation exercises focusing on lower limbs, 6 weeks, 3 sessions/week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (exercise booklet, 6 weeks, 3 sessions/week)
Number of subjects: 40
Study: 26773777

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) capsules at a dose of 1 g total catechin, primarily gallated type
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) capsules
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) intake
Number of subjects: 24
Study: 25262522

Group type: EXPERIMENTAL
Intervention: Danhong injection 20 ml
Number of subjects: 72

Group type: COMPARATOR
Intervention: Blood producing needle 400 mg (Control)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Comparison between experimental group and control group after treatment
Number of subjects: 72
Study: 22475545

Group type: EXPERIMENTAL
Intervention: anti-von Willebrand factor (vWF) Nanobody
Number of subjects: 110

Group type: COMPARATOR
Intervention: plasma exchange (as adjunctive therapy)
Number of subjects: 110
Study: 20078491

Group type: EXPERIMENTAL
Intervention: 0.05 mg nicotine yield cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.3 mg nicotine yield cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine lozenge
Number of subjects: 0
Study: 18329602

Group type: EXPERIMENTAL
Intervention: Weight Maintenance Intervention (MI) for 6 weeks after a 16-week behavioral weight loss program (BWLP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No Contact (NC) after a 16-week behavioral weight loss program (BWLP)
Number of subjects: 51
Study: 15776771

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream, once daily for 12 weeks
Number of subjects: 173

Group type: COMPARATOR
Intervention: Adapalene 0.1% cream, once daily for 12 weeks
Number of subjects: 173
Study: 12463291

Group type: EXPERIMENTAL
Intervention: Alendronate (specialists)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Alendronate (generalists)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Metformin (specialists)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Metformin (generalists)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Alpha1-blockers (specialists)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Alpha1-blockers (generalists)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Finasteride (specialists)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Finasteride (generalists)
Number of subjects: 2
Study: 10048071

Group type: EXPERIMENTAL
Intervention: Intra-operative neuromonitoring based on electrical stimulation of peripheral mixed nerve (tibial and median) and intra-operative subpial recording of conducted and interneuronic SEP from the dorsal surface of the spinal cord.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intra-operative neuromonitoring
Number of subjects: 30
Study: 8835620

Group type: EXPERIMENTAL
Intervention: Single oral dose of mefloquine 1250 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Divided doses of mefloquine (750 mg and 500 mg at 6-h intervals)
Number of subjects: 18
Study: 1823905

Group type: EXPERIMENTAL
Intervention: IMREG-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6119182

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (100 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Chlorthalidone + beta-blocker
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (100 mg/day) in subgroup IA (11 men)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Withdrawal of beta-blocker in subgroup IB (5 men, 2 post-menopausal women)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Clopamide (5 mg/day) in group II (18 men)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Clopamide + pindolol (10 mg/day)
Number of subjects: 35
Study: 31801373

Group type: EXPERIMENTAL
Intervention: High serum bilirubin levels
Number of subjects: 25406
Study: 30616288

Group type: EXPERIMENTAL
Intervention: Blue filter lens (BB)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ultraviolet blocking lens (UV)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Age-adjusted controls (AACs)
Number of subjects: 29
Study: 28397697

Group type: EXPERIMENTAL
Intervention: Leucovorin and fluorouracil plus nab-paclitaxel
Number of subjects: 114

Group type: COMPARATOR
Intervention: Gemcitabine plus nab-paclitaxel
Number of subjects: 114
Study: 24773119

Group type: EXPERIMENTAL
Intervention: Interactive educational intervention (n=133)
Number of subjects: 284

Group type: COMPARATOR
Intervention: No intervention (n=151)
Number of subjects: 284
Study: 23584593

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA 1 g/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 22010913

Group type: EXPERIMENTAL
Intervention: Earlier ART (2 weeks after starting tuberculosis treatment)
Number of subjects: 661

Group type: COMPARATOR
Intervention: Later ART (8 weeks after starting tuberculosis treatment)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Earlier ART
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 661
Study: 19251586

Group type: EXPERIMENTAL
Intervention: Mastery goal condition
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Normative performance goal condition
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Non-normative performance goal condition
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Performance-normative condition
Number of subjects: 324

Group type: COMPARATOR
Intervention: Performance non-normative condition
Number of subjects: 324
Study: 16923621

Group type: EXPERIMENTAL
Intervention: Spirometry and brief smoking cessation advice, annually for three years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smokers with COPD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smokers with normal lung function
Number of subjects: 0
Study: 14674053

Group type: EXPERIMENTAL
Intervention: Nefazodone (up to 600 mg daily)
Number of subjects: 28
Study: 10965288

Group type: EXPERIMENTAL
Intervention: Cognitive therapy by allocation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cognitive therapy by preference
Number of subjects: 66
Study: 8981691

Group type: EXPERIMENTAL
Intervention: Fixed combination of betaxolol (0.25%) and pilocarpine (1.75%), used 3 times daily in Studies 1 and 2; 2 times daily in Study 3.
Number of subjects: 534

Group type: COMPARATOR
Intervention: Betaxolol (0.25%) alone, used 3 times daily in Studies 1 and 2; 2 times daily in Study 3.
Number of subjects: 534

Group type: COMPARATOR
Intervention: Pilocarpine (1.75%) alone, used 3 times daily in Studies 1 and 2; 2 times daily in Study 3.
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Fixed combination of betaxolol and pilocarpine with surfactant, used 2 times daily in Study 3.
Number of subjects: 534